Skip to main content

Child IGA Efficacy Results

In the treatment of children (6-11 years) with uncontrolled moderate-to-severe atopic dermatitis

Clearer skin with DUPIXENT + TCS

Clearer skin demonstrated in children in AD-1652

AD-1652 6-11 YEARS
IGA 0 OR 1 AT WEEK 16
(primary endpoint)1-3,a,b

aFull Analysis Set includes all subjects randomized.1

bIn the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders.1

cAt Day 1, subjects (baseline weight <30 kg) received 600 mg of DUPIXENT.1

dAt Day 1, subjects (baseline weight ≥30 kg) received 400 mg of DUPIXENT.1

Visible results with DUPIXENT

Actual patients in a phase 3 pediatric DUPIXENT trial (AD-1652). All patients were prescribed concomitant TCS based on the clinical trial program. Patients 1, 2, and 3 were considered clinical responders. Individual results may vary.

In DUPIXENT clinical trials including children, the primary endpoint was the proportion of subjects with an Investigator’s Global Assessment (IGA) of 0 (clear) or 1 (almost clear) at Week 16.1

Patient 1: 6-year-old achieved a 3-point improvement in IGA4

DRAG TO SEE
RESULTS

Patient 2: 10-year-old achieved a 3-point improvement in IGA4

DRAG TO SEE
RESULTS

Patient 3: 9-year-old achieved a 3-point improvement in IGA4

DRAG TO SEE
RESULTS

Patient 4: 6-year-old achieved a 1-point improvement in IGA

DRAG TO SEE
RESULTS

A clinical responder was defined as a patient achieving IGA 0 or 11

  • Patient 4 did not meet the primary endpoint in the clinical trial based on their IGA score at Week 16

Explore more IGA efficacy results

View adult data VIEW ADOLESCENT (12 TO 17 YEARS) DATA VIEW INFANT TO PRESCHOOLER (6 MONTHS TO 5 YEARS) DATA

READY TO PRESCRIBE DUPIXENT?

DOSAGE AND ADMINISTRATION